← Back to Clinical Trials
Recruiting NCT05402488

NCT05402488 Exploring the Recovery Function of Sleep in Neurodegeneration

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05402488
Status Recruiting
Phase
Sponsor University of Zurich
Condition Neurodegenerative Diseases
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2022-03-14
Primary Completion 2025-12

Trial Parameters

Condition Neurodegenerative Diseases
Sponsor University of Zurich
Study Type INTERVENTIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-03-14
Completion 2025-12
Interventions
Auditory stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The overall objective of this study is to identify the best approach for assessing the recovery function of sleep in neurodegenerative diseases associated with abnormal protein aggregation with regard to the conception of future intervention studies. To this end, the investigators will follow an exploratory approach in a preferably broad data set collected in patients with neurodegenerative diseases associated with abnormal protein aggregation and in healthy humans.

Eligibility Criteria

Inclusion Criteria: * Good general health or confirmed diagnosis of neurodegenerative disease associated with abnormal protein aggregation along international criteria * Age above 18 years * In ambulant setting: ability to apply the ambulant EEG device for the duration of the study, either alone or with help of co-habitant if MoCA \< 20 Exclusion Criteria: * Failure to give informed consent * Inability to follow the procedures of the study, e.g. due to language problems or cognitive deficits * Known or suspected non-compliance, drug- or medication abuse * Inability to hear the tones to be applied during sleep in auditory stimulation experiments * Skin disorders/problems/allergies in face/ear area that could worsen with electrode application * Regular intake of drugs that may alter the relationship between sleep and outcome variables under investigation (opioids, benzodiazepines and z-drugs (nonbenzodiazepines)). * Clinically significant concomitant disease states * Too high (disease) b

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology